last day for compounded semaglutide & Tirzepatide 2025: Safe Use Guide Compounded Semaglutide (GLP-1)

The main difference is how the medication is taken, which your care team can help you decide

Aug 18: Regeneron Pharmaceuticals Veopoz (pozelimab) secured FDA approval as the first and only treatment indicated specifically for CHAPLE disease, also known as CD55-deficient protein-losing enteropathy, an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms

But the big key is we havent done a randomized controlled trial on this

Regarding serum lipid profiles, fasting TG decreased from 178.2105.3 to 159.391.6 with statistical significance in the EGCG group (p = 0.03)

Oral GLP-1 therapies are viewed as a major future growth segment because they can improve access and reduce injection-related barriers